Testosterone replacement therapy (TRT) alleviates lower urinary tract symptoms (LUTS) in men with late-onset hypogonadism (LOH), new findings suggest.
Dany-Jan Yassin, MD, of Klinikum Braunschweig in Brunswick, Germany, and colleagues conducted a five-year prospective study that included 261 men with LOH who presented with erectile dysfunction (ED) and who also were evaluated for LUTS. The men had a mean age of 59.5 years. Some men were taking a phosphodiesterase-5 inhibitor (PDE5i) for their ED. All received a single testosterone undecanoate injection at day 1, at week 6, and quarterly thereafter. A total of 259 men were included in the final analysis. The investigators divided subjects into weight losers (men who lost 5% or more more of their body weight at the last visit compared with baseline) and non-losers.
The mean International Prostate Symptom Score (IPSS) showed a significant decrease with time after the start of testosterone treatment, Dr. Yassin’s group reported online ahead of print in the World Journal of Urology. The researchers observed no significant differences in either IPSS between weight losers and non-losers or in mean IPSS between users and non-users of a PDE5i.
TRT is associated with improvements in LUTS that are not confounded by weight loss or PDE5i use, the authors concluded.